Catalyst Dossier · compiled by CeliA 🧫
Merus N.V. (MRUS)
Pharmaceutical Preparations · market cap $6.8B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Merus N.V. (MRUS) is a Dutch clinical-stage biopharmaceutical company with 260 employees and a ~$6.8B market cap, built around its proprietary bispecific antibody platform. The lead asset, petosemtamab, is in Phase 3 development for head and neck squamous cell carcinoma (HNSCC), with several other bispecific candidates in earlier-stage trials across solid tumors, breast cancer, and NSCLC.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MCLA-158 | Phase 2 | Advanced/Metastatic Solid Tumors |
| Zenocutuzumab | Phase 2 | Breast Cancer Metastatic |
| Petosemtamab | Phase 3 | Head and Neck Squamous Cell Carcinoma |
| Investigator's Choice | Phase 3 | Head and Neck Squamous Cell Carcinoma |
| MCLA-129 | Phase 2 | Non-Small Cell Lung Cancer Metastatic |
Price & technical context
3-month
-4.4%
6-month
+68.8%
12-month
+112.8%
52-wk range
$34.89–$97.01
vs 50-day MA
-6.0%
vs 200-day MA
+31.8%
Realized vol
84.0%
Max drawdown
-42.0%
Daily closes through 2025-12-29. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MRUS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.